Larimar Therapeutics, Inc.: Difference between revisions
>Paris Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. == References and notes == [..." |
(No difference)
|
Latest revision as of 23:45, 15 August 2022
Summary[1] edit edit source
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
References and notes edit edit source
- ↑ Source: Yahoo Finance.